ALBO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALBO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Albireo Pharma's total inventories for the quarter that ended in Sep. 2022 was $3.15 Mil. Albireo Pharma's average total inventories from the quarter that ended in Jun. 2022 to the quarter that ended in Sep. 2022 was $2.62 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Albireo Pharma's Net-Net Working Capital per share for the quarter that ended in Sep. 2022 was $0.21.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Albireo Pharma's Days Inventory for the three months ended in Sep. 2022 was 391.02.
Inventory Turnover measures how fast the company turns over its inventory within a year. Albireo Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.23.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Albireo Pharma's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 0.27.
The historical data trend for Albireo Pharma's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albireo Pharma Annual Data | |||||||||||||||||||||
Trend | Sep12 | Sep13 | Sep14 | Sep15 | Sep16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Total Inventories | Get a 7-Day Free Trial | - | - | - | - | 0.19 |
Albireo Pharma Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Total Inventories | Get a 7-Day Free Trial | 0.20 | 0.19 | 1.82 | 2.10 | 3.15 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Albireo Pharma (NAS:ALBO) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Albireo Pharma's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2022 is
Net-Net Working Capital Per Share (Q: Sep. 2022 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (222.476 | + | 0.75 * 2.029 | + | 0.5 * 3.149 | - | 221.151 |
- | 0 | - | 0) | / | 20.6927 | ||
= | 0.21 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Albireo Pharma's Days Inventory for the three months ended in Sep. 2022 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2022 ) | / | Cost of Goods Sold (Q: Sep. 2022 ) | * | Days in Period |
= | 2.6225 | / | 0.612 | * | 365 / 4 | |
= | 391.02 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Albireo Pharma's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Sep. 2022 ) | / | Average Total Inventories (Q: Sep. 2022 ) |
= | 0.612 | / | 2.6225 | |
= | 0.23 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Albireo Pharma's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Sep. 2022 ) | / | Revenue (Q: Sep. 2022 ) |
= | 2.6225 | / | 9.832 | |
= | 0.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Albireo Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Harford Simon N.r. | officer: CFO and Treasurer | AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
Pamela Stephenson | officer: Chief Commercial Officer | C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
Martha J. Carter | officer: Chief Regulatory Officer | C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960 |
Jan Mattsson | officer: Chief Operating Officer | C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109 |
Cooper Ronald Harold Wilfred | director, officer: President and CEO | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
Michelle Graham | officer: Chief Human Resources Officer | 10000 WEHRLE DRIVE, CLARENCE NY 14031 |
Jason Duncan | officer: General Counsel | C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109 |
Paul Streck | officer: Chief Medical Officer | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Craig C. Hopkinson | director | 852 WINTER STREET, WALTHAM MA 02451 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Susan Alesina | director | C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109 |
Habib J Dable | director | C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
Patrick Taylor Horn | officer: Chief Medical Officer | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By PRNewswire PRNewswire • 01-09-2023
By Value_Insider Value_Insider • 11-09-2022
By PRNewswire PRNewswire • 01-17-2023
By Stock market mentor Stock market mentor • 02-03-2023
By sperokesalga sperokesalga • 02-14-2023
By sperokesalga sperokesalga • 02-08-2023
By Business Wire Business Wire • 01-09-2023
By Tiesvg Tiesvg • 12-20-2022
By Value_Insider Value_Insider • 12-06-2022
By Value_Insider Value_Insider • 11-02-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.